Jing Shen

Jing Shen, MD PhD

Research Associate II

Education

M.D. Nanjing Medical University, 1985
MPH Nanjing Medical University, 1990
PhD, Peking University, 2001
Postdoctoral Training - Columbia University, 2004

Bio

Dr. Jing Shen’s current study focus' on HIV-1 latency reversal agents and potential mechanisms to eradicate HIV-1 infection. His previous studies were investigating HIV-1 mother-to-child transmission, outcomes of long-term HIV infection in children, as well as host epigenetic and mitochondrial changes in HIV-1 infected children. Other studies include cancer genomic, epigenomic alterations and interactions with environmental carcinogens in high-risk population.

Research Focus

HIV-1 Latency & Antagonists, Cancer Genomics & Epigenomics

Member of American Association of Cancer Research (AACR)

Shen J, Liberty A, Shiau S, et al. Mitochondrial Impairment in Well-Suppressed Children with Perinatal HIV-Infection on Antiretroviral Therapy. AIDS research and human retroviruses. 2020;36(1):27-38. doi:10.1089/AID.2018.0182.
Shen J, Liao Y, Hopper J, Goldberg M, Santella R, Terry M. Dependence of cancer risk from environmental exposures on underlying genetic susceptibility: an illustration with polycyclic aromatic hydrocarbons and breast cancer. British journal of cancer. 2017;116(9):1229-1233. doi:10.1038/bjc.2017.81.
Shen J, Wang Q, Gurvich I, Remotti H, Santella R. Evaluating normalization approaches for the better identification of aberrant microRNAs associated with hepatocellular carcinoma. Hepatoma research. 2016;2:305-315. doi:10.20517/2394-5079.2016.28.